AdBio partners

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in

Co-investorsRoche Venture FundBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.

BiotechHealthtechMedical DevicesAntwerp, BE

Tim Knotnerus(Chief Executive Officer)

Co-investorsEQT Life SciencesAndera PartnersAsabys PartnersCanaan PartnersPontifax Venture CapitalV-Bio Ventures+1 more

A suite of thematic Pipeline Builder Companies accelerating industrial development of promising academic biotech projects.

First thematic Pipeline Builder Company from the AndzonBio initiative, accelerating academic projects in cardiovascular, renal and metabolic (CVRM) disorders.

Andzon Bio develops breakthrough therapeutic programs targeting core disease mechanisms of underserved cardiovascular, renal, and metabolic (CVRM) conditions.

BiotechHealthtechParis, FR

Second thematic Pipeline Builder Company from the AndzonBio initiative, dedicated to neuroinflammation.

AndzonBio2 develops early-stage, mechanism-based therapies targeting neuroinflammation as a driver of neurological and neurodegenerative diseases.

BiotechHealthtech

Develops a disease-modifying approach in Cystic Fibrosis.

Clinical-stage biotech developing medicines through modulation of microRNAs; lead compound is ATX-01.

Co-investorsHadean VenturesSound Bioventures

Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease.

BiotechMedical Devices

Co-investorsInvivo Capital PartnersColumbus Venture PartnersSound Bioventures

Developing The Benchtop Cell Factory, an end-to-end platform for Cell and Gene Therapy manufacturing using microfluidic technology.

Co-investorsM Ventures

Co-investorsM Ventures

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.

BiotechMedical Devices

Co-investorsJeito CapitalNovo HoldingsPMVV-Bio VenturesAsabys Partners

Develops a first-in-class approach to thrombo-inflammation and vascular diseases.

Develops first-in-class KATP channel inhibitors for migraine treatment.

Cephagenix is a biotech company working on identifying and developing new treatments for migraine.

BiotechHealthtechParis, FR

Develops novel immune oncology agents for tumour-selective modulation of the microenvironment.

Developing first-in-class recombinant proteins for the treatment of type 1 diabetes.

Develops a first-in-class anti-FGFR4 mAb for cardiorenal disorders.

EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD).

BiotechDigital HealthLongevity

Co-investorsKurma Partners

Co-investorsInvivo Capital PartnersColumbus Venture Partners

Develops first-in-class antibodies targeting calcium signaling for auto-immune diseases.

Developing IPSC-MSC engineered cell therapy for inflammatory diseases.

KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction.

BiotechHealthtechMedical Devices

Miguel Forte(CEO)Tony Ting(CSO)Michel Andraud(CFO)Yen Wu(CBO)

Orikine Bio develops precision-engineered bi-specific cytokine therapies ("Foldikines") that reprogram immune signaling to treat severe autoimmune and inflammatory diseases.

BiotechDeep TechHealthtechBarcelona, ES

BoardLarry Edwards(Chairman of the Board)

Co-investorsAsabys Partners

Developing small molecules targeting the eIF4F complex in cancer.

The page promotes an online gambling/betting brand ("regalbet") presented as a digital gaming platform, using SEO-style marketing text targeting players in large cities.

Gaming

Develops gene therapy treatments for Inherited Retinal Diseases regardless of genetic cause.

Co-investorsJeito Capital

SparingVision is a genomic medicine company developing gene therapies for ophthalmic diseases, including SPVN06, a neuroprotective gene therapy for retinal conditions.

BiotechDeep TechDigital Health

Co-investorsJeito CapitalYsios Capital

Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.

BiotechDigital HealthHealthtechLongevityMedical Devices

Co-investorsF-Prime CapitalSofinnova Partners

Develops monoclonal antibody treatments for human mucosal inflammatory diseases.

Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody that targets extracellular AGR2 to treat inflammatory mucosal diseases.

BiotechMedical Devices

Develops first-in-class CD31-ITAM immune modulating bispecific antibodies for auto-immune and inflammatory disorders.

Co-investorsAdvent Life Sciences

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.

BiotechDeep TechHealthtechParis, FR

Co-investorsAdvent Life SciencesBioqube VenturesBpifrancePureos Bioventures

Co-investorsGlobal Health Investment CorporationIn-Q-Tel

Developing a structure-based drug discovery platform for readthrough compounds to treat cancer and rare diseases.

Urania Therapeutics develops treatments for genetic diseases and cancers caused by nonsense mutations, targeting monogenic diseases in which a single gene defect impairs production of a functional protein.

BiotechHealthtech

Develops small molecules inhibiting the non-canonical NF-κB2 pathway for cancer treatment.